Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion
暂无分享,去创建一个
G. Prendergast | A. P. Soler | J. DuHadaway | L. Mandik-Nayak | A. Muller | Alexander J. Muller | Erika Sutanto-Ward | Susan K. Gilmour | Janette Boulden | George C. Prendergast | Janette Boulden | Mee Young Chang | James B. DuHadaway | Arivudinambi Ramalingam | Alejandro P. Soler | Laura Mandik-Nayak | M. Chang | S. Gilmour | A. Ramalingam | E. Sutanto‐Ward
[1] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.
[2] B. Baban,et al. Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion1 , 2003, The Journal of Immunology.
[3] C. L. Costantino,et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. , 2009, Journal of the American College of Surgeons.
[4] D. Munn,et al. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.
[5] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[6] B. Baban,et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.
[7] G. Prendergast,et al. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. , 2010, Cancer research.
[8] Stefan Schneeberger,et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] K. Shirey,et al. Synergistic Transcriptional Activation of Indoleamine Dioxygenase by IFN-γ and Tumor Necrosis Factor-α , 2003 .
[10] Alberto Mantovani,et al. Inflammation and cancer: back to Virchow? , 2001, The Lancet.
[11] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.
[12] Minshan Chen,et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.
[13] M. Kazanietz,et al. Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.
[14] Hiroyasu Ito,et al. Serum concentration of L‐kynurenine predicts the clinical outcome of patients with diffuse large B‐cell lymphoma treated with R‐CHOP , 2010, European journal of haematology.
[15] G. Prendergast,et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.
[16] R. Peek,et al. Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. , 2005, Cancer research.
[17] Lloyd J. Old,et al. Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.
[18] A. Rudensky,et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.
[19] D. Galas,et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse , 2001, Nature Genetics.
[20] A. Mantovani,et al. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.
[21] N. Yanaihara,et al. Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells , 2005, Clinical Cancer Research.
[22] D. Munn,et al. The tumor‐draining lymph node as an immune‐privileged site , 2006, Immunological reviews.
[23] A. Cuenca,et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. , 2001, Blood.
[24] B. Pockaj,et al. Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO1 , 2006, The Journal of Immunology.
[25] Y. Shimoyama,et al. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma , 2009, Clinical & Experimental Metastasis.
[26] G. Hur,et al. The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells , 2009, Journal of immunotherapy.
[27] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.
[28] H. Schreiber,et al. The role of stroma in immune recognition and destruction of well-established solid tumors. , 2006, Current opinion in immunology.
[29] L. Coussens,et al. Inflammation and cancer , 2002, Nature.
[30] K. Shirey,et al. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[31] G. Prendergast,et al. Indoleamine 2,3-dioxygenase in immune suppression and cancer. , 2007, Current cancer drug targets.
[32] S. Mamidipalli,et al. Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity , 2009, Pharmacogenetics and genomics.
[33] P. Scherle,et al. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors , 2006, Nature Reviews Cancer.
[34] D. Munn,et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.
[35] J D Kemp,et al. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow , 1991, The Journal of experimental medicine.
[36] G. Prendergast,et al. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. , 2007, Cancer research.
[37] G. Prendergast,et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase , 2008, Proceedings of the National Academy of Sciences.
[38] L. Jermiin,et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. , 2007, Gene.
[39] G. Prendergast,et al. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. , 2007, Cancer research.
[40] D. Fuchs,et al. Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients , 2006, Dermatology.
[41] E. Jaffee,et al. Cancer immunologists and cancer biologists: why we didn't talk then but need to now. , 2007, Cancer research.
[42] H. Kajiyama,et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer , 2006, British Journal of Cancer.
[43] D. Munn,et al. Prevention of T cell–driven complement activation and inflammation by tryptophan catabolism during pregnancy , 2001, Nature Immunology.
[44] T. Gajewski. Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment , 2007, Clinical Cancer Research.
[45] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[46] O. Hayaishi,et al. Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.